GSK-1059615

DB11962InvestigationalSmall molecule

GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase mTOR and Phosphatidylinositol 3-kinase catalytic subunit type 3
Curator reviewed
Formula / weight: C₁₈H₁₁N₃O₂S · 333.37 g/mol (avg)
Code names: GSK1059615 · GSK-615

Resolves to

Compound

UNII07YMO87363CAS958852-01-2ChEMBLCHEMBL3544966PubChem23582824

Structure

InChIKeyQDITZBLZQQZVEE-YBEGLDIGSA-NSMILESO=C1NC(=O)\C(S1)=C\C1=CC=C2N=CC=C(C3=CC=NC=C3)C2=C1

Targets

P42345MTORQ8NEB9PIK3C3P48736PIK3CG

What you can answer from here — as of January 29, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

28Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with GSK-1059615, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account